DURECT (DRRX) Scheduled to Post Earnings on Wednesday

DURECT (NASDAQ:DRRX) is set to issue its quarterly earnings data after the market closes on Wednesday, November 13th. Analysts expect DURECT to post earnings of ($0.17) per share for the quarter.

DURECT (NASDAQ:DRRX) last posted its quarterly earnings data on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.05. The firm had revenue of $2.17 million for the quarter, compared to the consensus estimate of $2.49 million. DURECT had a negative net margin of 187.80% and a negative return on equity of 261.43%. During the same quarter in the prior year, the company posted ($0.46) earnings per share. On average, analysts expect DURECT to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

DURECT Stock Down 8.2 %

DRRX stock opened at $1.35 on Thursday. DURECT has a 52 week low of $0.47 and a 52 week high of $2.73. The stock has a market capitalization of $41.90 million, a PE ratio of -2.21 and a beta of 1.13. The firm has a 50 day moving average of $1.39 and a 200 day moving average of $1.35.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. HC Wainwright reiterated a “neutral” rating on shares of DURECT in a research note on Thursday, September 26th. StockNews.com started coverage on DURECT in a research report on Sunday. They set a “sell” rating for the company.

About DURECT

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.